Des-Arg9-[Leu8]-Bradykinin

Des-Arg9-[Leu8]-Bradykinin

For laboratory research purposes only. Not for human or veterinary use.

Cas No: 64695-06-3

Purity: ≥ 95%

Chemical Formula: C41H63N11O10

CAT.NO: P400843

Categories: , ,

Inquiry
Description

Product Name: Des-Arg9-[Leu8]-Bradykinin

Sequence One Letter Code: RPPGFSPL

Sequence Three Letter Code: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu

Cas No: 64695-06-3

Chemical Formula:C41H63N11O10

Molecular Weight: 870.1

Purity: ≥ 95%

Form: Lyophilized

Storage Conditions: - 20 °C

SMILES: CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N

IUPAC: (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid

INCHIKEY: BGAPYBBQGHUQNM-YYGRSCHNSA-N

INCHI:

InChI=1S/C41H63N11O10/c1-24(2)20-28(40(61)62)48-36(57)31-14-8-17-50(31)38(59)29(23-53)49-34(55)27(21-25-10-4-3-5-11-25)47-33(54)22-46-35(56)30-13-7-18-51(30)39(60)32-15-9-19-52(32)37(58)26(42)12-6-16-45-41(43)44/h3-5,10-11,24,26-32,53H,6-9,12-23,42H2,1-2H3,(H,46,56)(H,47,54)(H,48,57)(H,49,55)(H,61,62)(H4,43,44,45)/t26-,27-,28-,29-,30-,31-,32-/m0/s1

Conjugation: Unconjugated

Code Nacres: NA.28

Application: Des-Arg⁹-[Leu⁸]-Bradykinin is a synthetic peptide that functions as a selective antagonist of the bradykinin B1 receptor. By blocking B1 receptor-mediated signaling, this peptide is useful for dissecting inducible kinin pathways involved in inflammation, pain, vascular permeability, and cardiovascular responses. It is commonly used in pharmacological and physiological studies to distinguish B1 receptor-dependent effects from B2 receptor-mediated bradykinin signaling. Des-Arg⁹-[Leu⁸]-Bradykinin supports research on chronic inflammatory disease models, vascular dysfunction, kinin receptor pharmacology, pain sensitization, and therapeutic strategies targeting pathological B1 receptor activation. 

Get a Quote

No products in the cart.